Inotuzumab ozogamicin therapy for measurable residual disease in adult acute lymphoblastic leukemia
{{output}}
Inotuzumab ozogamicin, an anti-CD22 antibody-drug conjugate, has demonstrated high response rates and measurable residual disease (MRD)-negativity in acute lymphoblastic leukemia (ALL). This phase 2 single-center study evaluated inotuzumab 0.6 mg/m2 day 1 and ... ...
